GEN Exclusives

More »

Feature Articles

More »
Sep 15, 2008 (Vol. 28, No. 16)

Metabolite Profiling Speeds Diagnostic Efforts

Early Detection of Diseases Could Be Substantially Aided by Metabolomics

  • Metabolomics is a member of an unruly menagerie of omics creatures, whose pedigrees trace back to the grandfather of all omics-genomics. Omics is now defined as an all-encompassing study of some area of the biological sciences. This includes what appears to be great stretches of linguistic invention as well as a vast capacity for broad generalization such as the speechome, the exposome, and the metallome.

    Currently, there is great interest in metabolomics, which is defined as the comprehensive set of low molecular weight metabolites comprising a biological sample—such as a single organism, a group such as a population of individuals or a species—and the interactions that drive the system and provide its dynamic collection of interactions.

    To invest some order to its study and evaluation, investigators at the Universities of Alberta and Calgary recently completed the first draft of the human metabolome, consisting of approximately 2,500 metabolites. This ome, or totality of the metabolome, is available at the Human Metabolome Database. It is far from complete, however, so it can be called an ome only in a partial or a relative sense.

    In contrast, much more is known about the metabolomes of other organisms, especially plants. Metabolomics is quite a different undertaking from proteomics or genomics, in which one characterizes the actual genetic makeup of a living system.

    The metabolome could represent drugs and other exogenous agents and an army of small molecules whose presence will change radically reflecting the particular metabolic and environmental state of the subject. The biochemical charts of metabolic pathways that identify the thousands of intermediates across the cell and their relative levels form the blueprint of the metabolome.

    The state of field will be discussed at the Metabolomics Society’s annual meeting in Boston this month. Some of the speakers gave GEN a preview of their presentations.

  • Endogenous Metabolites

    “In all stages of biomarker discovery, it is extremely important to know the identities of differentially expressed metabolic components as compared to viewing them solely as statistical objects,” states Robert Mistrik, Ph.D., and CEO at HighChem, who will discuss the challenges posed by structural profiling of endogenous metabolites.

    Metabolic profiling, a widely used tool today, compares two groups of individuals —a sample of normal controls and a matched group of diseased individuals. Scanning the levels of many metabolites, profiles for individuals can be obtained and differences noted between the various groups. Consistent alterations in metabolite expression can reveal significant features of a disease process not obtainable through other approaches.

    The company’s main thrust is the development of software solutions for crunching complex analytical data. The analysis is aimed at low molecular weight substances, that is, nonpeptide or proteinaceous materials. Other areas of interest include comprehensive libraries of fragmentation knowledge and experimental spectral data.

    Much of the company’s efforts involve the development of an accurate mass search tool for analyzing structural libraries. The traditional approaches adopted by HighChem include spectra searches against reference libraries, multivariate pattern-recognition methods, biochemical pathway analysis, and direct spectra interpretation.

    To facilitate this analysis, HighChem is pursuing an extension of its spectral library of endogenous metabolites referred to as spectral trees, according to Dr. Mistrik. Mass spectrometers are usually coupled to either liquid chromatography or gas chromatography devices, which yield data with divergent properties resulting from the different features of the two separation technologies.

    HighChem software allows the spectral trees to be reconstructed from data files, extracting and comparing informative data from both LC and GC characterization. “It is possible to store and search trees in libraries, to annotate every node spectrum or to create chromatographic libraries with spectral tree components,” states Dr. Mistrik.

    One of the important collaborative efforts that HighChem is involved in is the METAcancer project, a large consortium currently investigating breast cancer in the EU. The company is investigating new biomarkers for early detection of breast cancer as part of the project.

  • Focus on Prostate Cancer

    Metabolon is developing diagnostic tests based on metabolomic profiling for prostate cancer, diabetes, and other diseases, according to Jeffrey Shuster, Ph.D., director of diagnostics development. The company has built a platform using gas and liquid chromatography in combination with mass spectrometry for identification of metabolic differences between normal and affected individuals. Ideally, the populations should be balanced with respect to age, sex, race, diet, and lifestyle, although in the real world this may not always be possible.

    “Through metabolomics, we believe that we can bring new diagnostics to market faster and more efficiently by sidestepping much of the research effort required to characterize new markers by traditional methods,” Dr. Shuster explains.

    Metabolon is also focused on prostate cancer. The company is developing profiles that will discriminate normal and cancer-ridden individuals on the basis of metabolites in urine and serum and also analyze the differences between indolent and aggressive tumors among the positive cases.

    The primary goal of the project is to reduce the number of biopsies that are performed while at the same time producing a more accurate diagnosis. Another goal is to produce metabolic profiles that ascertain the level of aggressivity.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Lab-Grown Vaginas

Which body part do you think will be successfully engineered in the lab next?